

# Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Marina C. Garassino, MD<sup>1,2</sup>; Shirish Gadgeel, MD<sup>3</sup>; Giovanna Speranza, MD, MSc<sup>4</sup>; Enriqueta Felip, MD, PhD<sup>5</sup>; Emilio Esteban, MD<sup>6</sup>; Manuel Dómine, MD<sup>7</sup>; Maximilian J. Hochmair, MD<sup>8</sup>; Steven F. Powell, MD<sup>9</sup>; Helge G. Bischoff, MD<sup>10</sup>; Nir Peled, MD<sup>11</sup>; Francesco Grossi, MD<sup>12</sup>; Ross R. Jennens, MBBS<sup>13</sup>; Martin Reck, MD, PhD<sup>14</sup>; Rina Hui, MBBS, PhD<sup>15</sup>; Edward B. Garon, MD<sup>16</sup>; Takayasu Kurata, MD<sup>17</sup>; Jhanelle E. Gray, MD<sup>18</sup>; Paul Schwarzenberger, MD<sup>19</sup>; Erin Jensen, MS<sup>19</sup>; M. Catherine Pietanza, MD<sup>19</sup>; and Delys Rodríguez-Abreu, MD, PhD<sup>20</sup>

## abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.

We present 5-year outcomes from the phase 3 KEYNOTE-189 study (ClinicalTrials.gov identifier: [NCT02578680](https://clinicaltrials.gov/ct2/show/study/NCT02578680)). Eligible patients with previously untreated metastatic nonsquamous non–small-cell lung cancer without *EGFR/ALK* alterations were randomly assigned 2:1 to pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles with pemetrexed and investigator’s choice of carboplatin/cisplatin for four cycles, followed by maintenance pemetrexed until disease progression or unacceptable toxicity. Primary end points were overall survival (OS) and progression-free survival (PFS). Among 616 randomly assigned patients (n = 410, pembrolizumab plus pemetrexed-platinum; n = 206, placebo plus pemetrexed-platinum), median time from random assignment to data cutoff (March 8, 2022) was 64.6 (range, 60.1–72.4) months. Hazard ratio (95% CI) for OS was 0.60 (0.50 to 0.72) and PFS was 0.50 (0.42 to 0.60) for pembrolizumab plus platinum-pemetrexed versus placebo plus platinum-pemetrexed. 5-year OS rates were 19.4% versus 11.3%. Toxicity was manageable. Among 57 patients who completed 35 cycles of pembrolizumab, objective response rate was 86.0% and 3-year OS rate after completing 35 cycles (approximately 5 years after random assignment) was 71.9%. Pembrolizumab plus pemetrexed-platinum maintained OS and PFS benefits versus placebo plus pemetrexed-platinum, regardless of programmed cell death ligand-1 expression. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care in previously untreated metastatic non–small-cell lung cancer without *EGFR/ALK* alterations.

J Clin Oncol 41:1992-1998. © 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

## ASSOCIATED CONTENT

## Appendix

## Protocol

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on December 15, 2022 and published at [ascopubs.org/journal/jco](https://ascopubs.org/journal/jco) on February 21, 2023; DOI <https://doi.org/10.1200/JCO.22.01989>

## INTRODUCTION

In the phase 3 KEYNOTE-189 study, pembrolizumab (an anti–programmed cell death protein-1 monoclonal antibody) plus pemetrexed and carboplatin/cisplatin significantly prolonged overall survival (OS; hazard ratio [HR], 0.49; 95% CI, 0.38 to 0.64;  $P < .001$ ) and progression-free survival (PFS; 0.52; 0.43 to 0.64;  $P < .001$ ) versus placebo plus pemetrexed-platinum in previously untreated metastatic nonsquamous non–small-cell lung cancer (NSCLC) without *EGFR/ALK* alterations.<sup>1</sup> In the protocol-specified final analysis, OS and PFS continued to improve with HRs (95% CI) of 0.56 (0.46 to 0.69) and 0.49 (0.41 to 0.59), respectively.<sup>2</sup> We present a 5-year exploratory analysis from KEYNOTE-189.

## METHODS

## Study Design and Patients

The study design for KEYNOTE-189 (ClinicalTrials.gov identifier: [NCT02578680](https://clinicaltrials.gov/ct2/show/study/NCT02578680)) has been previously described.<sup>1-3</sup> The Protocol (online only) and its amendments were approved by the appropriate institutional review boards and ethics committees. Patients provided written informed consent before enrollment.

Patients were randomly assigned 2:1 to pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles (approximately 2 years). Patients also received pemetrexed 500 mg/m<sup>2</sup> plus cisplatin 75 mg/m<sup>2</sup> or carboplatin area under the curve 5 mg/mL/min once every 3 weeks for four cycles followed by pemetrexed

## CONTEXT

### Key Objective

We examined whether patients with previously untreated metastatic nonsquamous non–small-cell lung cancer without *EGFR/ALK* alterations treated with pembrolizumab plus pemetrexed and platinum chemotherapy continue to experience improved survival outcomes versus placebo plus pemetrexed and platinum chemotherapy after 5 years of follow-up.

### Knowledge Generated

After 5 years, pembrolizumab plus pemetrexed-platinum was associated with improved overall survival (OS) and progression-free survival compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non–small-cell lung cancer, regardless of programmed cell death ligand-1 expression. Five-year OS rates were 19.4% versus 11.3% in the intention-to-treat population.

### Relevance (T.E. Stinchcombe)

The 5-year follow-up demonstrates durable benefit for the combination of platinum-pemetrexed and pembrolizumab and the benefit in the subsets of patients on the basis of tumor programmed cell death ligand-1 expression. In the future, the landmark analyses of progression-free survival or OS at 3 or 5 years may be used to assess the long-term benefit of novel immunotherapies.\*

\*Relevance section written by JCO Associate Editor Thomas E. Stinchcombe, MD.

maintenance therapy. Treatment continued until the maximum number of cycles or until radiographic progression, unacceptable toxicity, investigator's decision, or patient withdrawal. Patients in the placebo plus pemetrexed-platinum group could cross over to receive pembrolizumab monotherapy upon documented progressive disease (PD) per RECIST v1.1 by blinded independent central review (BICR) if eligibility criteria were met. Patients could receive a second course of pembrolizumab monotherapy for up to 17 cycles (approximately 1 year) upon PD after either completing 35 cycles of pembrolizumab with a best overall response of stable disease or better or having achieved confirmed investigator-assessed complete response (CR) after receiving  $\geq 8$  cycles of pembrolizumab and  $\geq 2$  cycles beyond the initial CR assessment.

### End Points and Statistical Analysis

Primary end points were PFS per RECIST v1.1 by BICR and OS. Secondary end points were objective response rate (ORR) and duration of response (DOR) per RECIST v1.1 by BICR and safety. Exploratory end points included PFS2 (time from random assignment to second/subsequent PD on next-line treatment or death from any cause). No alpha was assigned to this analysis.

## RESULTS

### Patients

Overall, 616 patients were randomly assigned to pembrolizumab plus pemetrexed-platinum ( $n = 410$ ) or placebo plus pemetrexed-platinum ( $n = 206$ ; [Table 1](#)). At data cutoff (March 8, 2022), seven patients (all in the pembrolizumab plus pemetrexed-platinum group) were continuing to

receive pemetrexed. Among patients randomly assigned to pembrolizumab plus pemetrexed-platinum, 224 (54.6%) received subsequent anticancer therapy (103 received anti-PD-1 or anti-programmed cell death ligand 1 [PD-L1] therapy, including nine who began on-study second-course pembrolizumab; [Appendix Table A1](#), online only). In the placebo plus pemetrexed-platinum group, 84 patients crossed over to pembrolizumab monotherapy on-study; an additional 34 patients received subsequent anti-PD-(L)1 therapy outside the study for an effective crossover rate of 57.3%.

### Efficacy Outcomes

Median time from random assignment to data cutoff was 64.6 (range, 60.1-72.4) months. In the intention-to-treat (ITT) population, HRs (95% CI) for pembrolizumab plus pemetrexed-platinum versus placebo plus pemetrexed-platinum were 0.60 (0.50 to 0.72) for OS and 0.50 (0.42 to 0.60) for PFS ([Figs 1A and 1E](#)). Five-year OS rates were 19.4% versus 11.3%, and 5-year PFS rates were 7.5% versus 0.6%. ORR (95% CI) was 48.3% (43.4 to 53.2) and 19.9% (14.7 to 26.0), respectively. Median (range) DOR was 12.7 (1.1+ to 68.3+) and 7.1 (2.4 to 31.5) months, respectively ([Fig 2A](#)). Similar trends were observed across the PD-L1 subgroups analyzed ([Figs 1B-1D, 1F-1H](#); [Appendix Table A2](#) [online only]; and [Appendix Fig A1](#) [online only]).

Median (95% CI) PFS2 was 17.0 (15.0 to 19.2) months in the pembrolizumab plus pemetrexed-platinum group versus 9.1 (7.6 to 10.8) months in the placebo plus pemetrexed-platinum group (HR, 0.54; 95% CI, 0.45 to 0.65). Five-year PFS2 rates (95% CI) were 16.7% (13.2 to 20.5) versus 7.8% (4.7 to 12.1).

**TABLE 1.** Patient Baseline Characteristics

Characteristic	Pembrolizumab Plus Chemotherapy (n = 410)	Placebo Plus Chemotherapy (n = 206)	Completed 35 Cycles of Pembrolizumab (n = 57)
Age, years, median (range)	65.0 (34-84)	63.5 (34-84)	66.0 (42-82)
Sex			
Male	254 (62.0)	109 (52.9)	34 (59.6)
Female	156 (38.0)	97 (47.1)	23 (40.4)
ECOG performance status			
0	185 (45.1)	79 (38.3)	35 (61.4)
1	221 (53.9)	126 (61.2)	22 (38.6)
2	1 (0.2)	0	0
Missing	3 (0.7)	1 (0.5)	0
Smoking status			
Former or current	362 (88.3)	181 (87.9)	52 (91.2)
Never	48 (11.7)	25 (12.1)	5 (8.8)
Histology			
Adenocarcinoma	394 (96.1)	199 (96.6)	57 (100.0)
NSCLC not otherwise specified	10 (2.4)	4 (1.9)	0
Other	6 (1.5)	3 (1.5)	0
Brain metastases	73 (17.8)	35 (17.0)	6 (10.5)
Liver metastases	66 (16.1)	50 (24.3)	8 (14.3)
PD-L1 TPS <sup>a</sup>			
< 1%	127 (31.0)	63 (30.6)	6 (10.5)
≥ 1%	260 (63.4)	128 (62.1)	48 (84.2)
1%-49%	128 (31.2)	58 (28.2)	17 (29.8)
≥ 50%	132 (32.2)	70 (34.0)	31 (54.4)
Could not be evaluated	23 (5.6)	15 (7.3)	3 (5.3)
Platinum chemotherapy			
Cisplatin	113 (27.6)	58 (28.2)	17 (29.8)
Carboplatin	297 (72.4)	148 (71.8)	40 (70.2)
Prior therapy			
Thoracic radiotherapy	29 (7.1)	19 (9.2)	5 (8.8)
Neoadjuvant therapy	5 (1.2)	6 (2.9)	0
Adjuvant therapy	25 (6.1)	14 (6.8)	5 (8.8)

NOTE. Data are No. (%) unless noted otherwise.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small-cell lung cancer; PD-L1, programmed cell death ligand 1; TPS, tumor proportion score.


<sup>a</sup>PD-L1 expression was determined by PD-L1 IHC 22C3 pharmDx (Agilent Technologies, Carpinteria, CA), as previously described.<sup>1</sup>

### Safety


Overall, 404 patients (99.8%) in the pembrolizumab plus pemetrexed-platinum group and 200 (99.0%) in the placebo plus pemetrexed-platinum group experienced adverse events (AEs). All fatal AEs were previously reported.<sup>2,3</sup> Immune-mediated AEs and infusion reactions occurred in 113 (27.9%) and 27 (13.4%) patients, respectively (Appendix Table A3, online only).

### Patients Who Completed 35 Cycles of Pembrolizumab

Of the patients randomly assigned to pembrolizumab plus pemetrexed-platinum, 57 (13.9%) completed 35 cycles of pembrolizumab (Table 1) and received a median of 35 (range, 2-98) cycles of pemetrexed. ORR was 86.0% (8 CRs, 41 partial responses) and eight patients had best response of stable disease (Fig 2B). Median DOR was 57.7 (range, 4.2 to 68.3+) months. Estimated OS rate 3 years



**FIG 1.** Kaplan-Meier estimates of OS in the (A) ITT, (B) PD-L1 TPS ≥ 50%, (C) PD-L1 TPS 1%-49%, and (D) PD-L1 TPS < 1% populations and PFS by RECIST version 1.1 by blinded independent central review in the (E) ITT, (F) PD-L1 TPS ≥ 50%, (G) PD-L1 TPS 1%-49%, and (H) PD-L1 TPS < 1% populations. Chemo, chemotherapy; ITT, intention-to-treat; OS, overall survival; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; TPS, tumor proportion score.



**FIG 2.** (A) Duration of response in the ITT population and (B) treatment duration and time to response in patients who completed 35 cycles of pembrolizumab. Response assessments are shown per RECIST version 1.1 by BICR. Median PFS was not reached (95% CI, 14.7 months to not reached). PFS rate 3 years after completion of 35 cycles was 56.2% (95% CI, 39.7 to 69.8). BICR, blinded independent central review; chemo, chemotherapy; CR, complete response; ITT, intention-to-treat; PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.

after completion of 35 cycles (ie, approximately 5 years from random assignment) was 71.9% (95% CI, 58.3 to 81.8). At data cutoff, 23 of 57 patients (40.4%) were alive without PD or subsequent therapy.

All patients experienced  $\geq 1$  AE (grade 3/4 AEs, 38 [66.7%]); none were grade 5. Immune-mediated AEs and infusion reactions occurred in 23 patients (40.4%; grade 3/4 in 7 [12.3%]).

## DISCUSSION

In this 5-year update from KEYNOTE-189, pembrolizumab plus pemetrexed-platinum continued to prolong OS and PFS regardless of PD-L1 expression versus placebo plus pemetrexed-platinum with manageable toxicity (consistent with previous reports)<sup>2,3</sup> in patients with previously untreated metastatic nonsquamous NSCLC without *EGFR/ALK* alterations. Five-year OS rate was approximately 20% with pembrolizumab plus pemetrexed-platinum in the ITT population (*v* 11% with placebo plus pemetrexed-platinum) and was higher in patients with higher PD-L1 tumor proportion score (TPS), especially in the TPS  $\geq 50\%$  subgroup (29.6% *v* 21.4%; similar to the 5-year OS rates in the KEYNOTE-024 study of pembrolizumab monotherapy *v* chemotherapy [31.9% *v* 16.3%]<sup>14</sup>). However, there were a limited number of patients at risk at 5 years in some subgroups. Importantly, benefits were also observed in the PD-L1 TPS < 1% subgroup, for whom pembrolizumab monotherapy is not indicated.

Sustained improvements in OS were observed with pembrolizumab plus pemetrexed-platinum versus placebo plus pemetrexed-platinum despite an effective crossover rate of 57% from placebo plus pemetrexed-platinum to subsequent anti-PD-(L)1 therapy, which is reflected in the plateauing of the placebo plus pemetrexed-platinum Kaplan-Meier curve and was not

previously observed in studies of chemotherapy alone.<sup>5</sup> These factors likely attenuated the differences in 5-year OS rates in the ITT population and in OS HR observed in later analyses compared with the first interim analysis.<sup>1</sup> The improvement in PFS2 with pembrolizumab plus pemetrexed-platinum versus placebo plus pemetrexed-platinum also suggests the benefit of pembrolizumab plus pemetrexed-platinum is maintained after initial disease progression, further supporting its use as first-line treatment.

Pembrolizumab demonstrated robust and durable antitumor activity in patients who completed 35 cycles of pembrolizumab, with a majority of patients (72%) alive 3 years after completion (approximately 5 years after random assignment). These data support the feasibility of a 2-year treatment duration with pembrolizumab plus pemetrexed-platinum and are consistent with the outcomes reported in patients who completed 35 cycles of pembrolizumab monotherapy<sup>6,7</sup> and in the KEYNOTE-407 study of pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel versus placebo plus carboplatin and paclitaxel/nab-paclitaxel in previously untreated metastatic squamous NSCLC.<sup>8</sup> Although this is the first report of 5-year outcomes for anti-PD-(L)1 therapy plus chemotherapy from a phase 3 study, improved survival outcomes at 5 years were reported with nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) versus chemotherapy in the CheckMate 227 study.<sup>9</sup>

In conclusion, pembrolizumab plus pemetrexed-platinum continued to demonstrate prolonged survival and durable antitumor activity versus placebo plus pemetrexed-platinum after 5 years of follow-up, with manageable toxicity,<sup>2</sup> in patients with previously untreated metastatic nonsquamous NSCLC without *EGFR/ALK* alterations. These results continue to support the combination of first-line pembrolizumab plus a platinum and pemetrexed as a standard of care for these patients.

## AFFILIATIONS

<sup>1</sup>Knapp Center for Biomedical Discovery, University of Chicago Medicine & Biological Sciences, Chicago, IL

<sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

<sup>3</sup>Henry Ford Cancer Institute/Henry Ford Health, Detroit, MI

<sup>4</sup>Centre Intégré de Cancérologie de la Montérégie, Hôpital Charles-Le Moyne, Greenfield Park, QC, Canada

<sup>5</sup>Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

<sup>6</sup>Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain

<sup>7</sup>Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain

<sup>8</sup>Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria

<sup>9</sup>Hematology and Oncology, Sanford Cancer Center, Sioux Falls, SD

<sup>10</sup>Thoraxklinik, Heidelberg, Germany

<sup>11</sup>Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel

<sup>12</sup>Medical Oncology Division, University of Insubria, Varese, Italy

<sup>13</sup>Department of Medical Oncology, Epworth Healthcare, Richmond, VIC, Australia

<sup>14</sup>LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany

<sup>15</sup>Department of Medical Oncology, Westmead Hospital and University of Sydney, Sydney, NSW, Australia

<sup>16</sup>Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA

<sup>17</sup>Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan

<sup>18</sup>Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL

<sup>19</sup>Merck & Co, Inc, Rahway, NJ

<sup>20</sup>Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain

## CORRESPONDING AUTHOR

Marina C. Garassino, MD, Knapp Center for Biomedical Discovery (KCBD), University of Chicago Medicine & Biological Sciences, 900 East 57th St 7132 A, Chicago, IL 60637; e-mail: mgarassino@medicine.bsd.uchicago.edu.

## PRIOR PRESENTATION

Presented at the European Society for Medical Oncology Congress, Paris, France, September 9-13, 2022.

## SUPPORT

Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ.

## CLINICAL TRIAL INFORMATION

NCT02578680

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.22.01989>.

## DATA SHARING STATEMENT

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ (MSD), is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company's clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data sharing website (available at: [http://engagezone.msd.com/ds\\_documentation.php](http://engagezone.msd.com/ds_documentation.php)) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the United States and European Union or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country- or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD subject matter experts; after

approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Maximilian J. Hochmair, Helge G. Bischoff, Martin Reck, Jhanelle E. Gray, Paul Schwarzenberger, M. Catherine Pietanza, Delvys Rodríguez-Abreu

**Administrative support:** Enriqueta Felip, Maximilian J. Hochmair, Helge G. Bischoff

**Provision of study materials or patients:** Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Manuel Dómine, Steven F. Powell, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Jhanelle E. Gray, Delvys Rodríguez-Abreu

**Collection and assembly of data:** Marina C. Garassino, Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Maximilian J. Hochmair, Steven F. Powell, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Paul Schwarzenberger, M. Catherine Pietanza, Delvys Rodríguez-Abreu

**Data analysis and interpretation:** Marina C. Garassino, Shirish Gadgeel, Enriqueta Felip, Manuel Dómine, Maximilian J. Hochmair, Steven F. Powell, Helge G. Bischoff, Nir Peled, Ross R. Jennens, Martin Reck, Rina Hui, Jhanelle E. Gray, Paul Schwarzenberger, Erin Jensen, M. Catherine Pietanza, Delvys Rodríguez-Abreu

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## ACKNOWLEDGMENT

The authors thank the patients and their families and caregivers for participating in this study, along with all investigators and site personnel. Additional study support was provided by Gregory M. Lubiniecki, MD, and Mark Shamoun, MD, of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ. Eli Lilly provided pemetrexed but had no additional role in trial conduct. Medical writing assistance was provided by Kathleen Estes, PhD, and Shilpa Kamboj, PhD, of ICON plc (Blue Bell, PA). This assistance was funded by MSD.

## REFERENCES

- Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med* 378:2078-2092, 2018
- Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al: Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: Protocol-specified final analysis from KEYNOTE-189. *Ann Oncol* 32:881-895, 2021
- Gadgeel S, Rodríguez-Abreu D, Speranza G, et al: Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. *J Clin Oncol* 38:1505-1517, 2020
- Reck M, Rodríguez-Abreu D, Robinson AG, et al: Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score  $\geq$  50. *J Clin Oncol* 39:2339-2349, 2021
- Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 346:92-98, 2002
- Reck M, Rodríguez-Abreu D, Robinson AG, et al: Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score  $\geq$  50. *J Clin Oncol* 39:2339-2349, 2021
- de Castro G, Kudaba I, Wu Y-L, et al: Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score  $\geq$  1% in the KEYNOTE-042 study. *J Clin Oncol* 41:1986-1991, 2023
- Novello S, Kowalski DM, Luft A, et al: Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. *J Clin Oncol* 41:1999-2006, 2023
- Brahmer JR, Lee J-S, Ciuleanu T-E, et al: Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (NSCLC): Results from CheckMate 227. *J Clin Oncol* 40, 2022 (suppl abstr LBA9025)



**AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST****Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/authors/author-center](http://ascopubs.org/jco/authors/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://Open Payments)).

**Marina C. Garassino**

**Honoraria:** MSD Oncology, AstraZeneca/MedImmune, GlaxoSmithKline, Takeda, Roche, Bristol Myers Squibb

**Consulting or Advisory Role:** Bristol Myers Squibb, MSD, AstraZeneca, Novartis, Takeda, Roche, Tiziana Life Sciences, Sanofi, Celgene, Daiichi Sankyo, Inivata, Incyte, Pfizer, Seattle Genetics, Lilly, GlaxoSmithKline, Bayer, Blueprint Medicines, Janssen, Regeneron

**Speakers' Bureau:** AstraZeneca, Takeda, MSD Oncology, Celgene, Incyte, Roche, Bristol Myers Squibb, Otsuka, Lilly

**Research Funding:** Bristol Myers Squibb (Inst), MSD (Inst), Roche/Genentech (Inst), AstraZeneca/MedImmune (Inst), AstraZeneca (Inst), Pfizer (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Merck (Inst), Incyte (Inst), Takeda (Inst), Spectrum Pharmaceuticals (Inst), Blueprint Medicines (Inst), Lilly (Inst), Ipsen (Inst), Janssen (Inst), Exelixis (Inst), MedImmune (Inst), Sanofi (Inst), Amgen (Inst)

**Travel, Accommodations, Expenses:** Pfizer, Roche, AstraZeneca

**Shirish Gadgee**

**Honoraria:** Merck

**Consulting or Advisory Role:** Genentech/Roche, AstraZeneca, Bristol Myers Squibb, Takeda, Daiichi-Sanyko, Novartis, Blueprint Medicines, Lilly, Pfizer, Janssen Oncology, Mirati Therapeutics, Merck, Esai Pharma, Gilead Sciences, GlaxoSmithKline

**Research Funding:** Genentech/Roche (Inst), Merck (Inst), Blueprint Medicines (Inst), Astellas Pharma (Inst), Daiichi Sankyo (Inst), I-Mab (Inst), Nektar (Inst), AstraZeneca (Inst), Pfizer (Inst), Amgen (Inst), Turning Point Therapeutics (Inst), Regeneron (Inst), Mirati Therapeutics (Inst), Janssen Oncology (Inst), BioMed Valley Discoveries (Inst), Ymabs Therapeutics Inc (Inst), Calithera Biosciences (Inst), InventisBio (Inst), Daiichi Sanyko (Inst), Dragonfly Therapeutics (Inst), eFFECTOR Therapeutics (Inst), Elevation Oncology (Inst), Erasca, Inc (Inst), Helsinn Therapeutics (Inst), Incyte (Inst), Numab (Inst), Verastem (Inst)

**Travel, Accommodations, Expenses:** Mirati Therapeutics

**Other Relationship:** AstraZeneca

**Giovanna Speranza**

**Consulting or Advisory Role:** Bayer

**Enriqueta Felip**

**Consulting or Advisory Role:** Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Pfizer, Sanofi, Takeda, Peptomyc, Daiichi Sankyo Europe GmbH, F. Hoffmann LaRoche, Merck Sharp & Dohme

**Speakers' Bureau:** AstraZeneca, Bristol Myers Squibb, Lilly, Medscape, Merck Sharp & Dohme, PeerVoice, Pfizer, Takeda, Amgen, F. Hoffmann LaRoche, Janssen, Medical Trends, Merck Serono, Sanofi, TouchONCOLOGY

**Research Funding:** Merck (Inst), Merck KGaA (Inst)

**Other Relationship:** GRIFOLS

**Emilio Esteban**

**Travel, Accommodations, Expenses:** Pfizer/EMD Serono

**Manuel Dómine**

**Consulting or Advisory Role:** AstraZeneca, Bristol Myers Squibb, MSD Oncology, Pfizer, Roche, Takeda

**Maximilian J. Hochmair**

**Consulting or Advisory Role:** Takeda, Roche, Lilly, AstraZeneca/Daiichi Sankyo

**Speakers' Bureau:** Lilly, MSD Oncology, Novartis, Roche

**Steven F. Powell**

**Consulting or Advisory Role:** Bristol Myers Squibb (Inst)

**Speakers' Bureau:** Alkermes (Inst)

**Research Funding:** Merck Sharp & Dohme (Inst), Novartis (Inst), Genentech/Roche (Inst), Incyte (Inst), Bristol Myers Squibb (Inst), Pfizer (Inst), Vyriad (Inst), Actuate Therapeutics (Inst), AstraZeneca/MedImmune (Inst), Seattle Genetics (Inst), Sorrento (Inst)

**Francesco Grossi**

**Consulting or Advisory Role:** MSD Oncology, Bristol Myers Squibb, AstraZeneca, Roche, Pfizer, Bayer, Lilly, Novartis Italy, Sanofi

**Speakers' Bureau:** MSD Oncology, Bristol Myers Squibb, AstraZeneca, Roche, Pierre Fabre, Amgen, Celgene, Lilly, Pfizer, Sanofi

**Research Funding:** Bristol Myers Squibb

**Travel, Accommodations, Expenses:** Bristol Myers Squibb, MSD, Roche, AstraZeneca, Pierre Fabre, Celgene, Amgen, Lilly, Novartis

**Martin Reck**

**Consulting or Advisory Role:** Lilly, MSD Oncology, Merck Serono, Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, Roche/Genentech, AbbVie, Amgen, Mirati Therapeutics, Samsung Bioepis, Sanofi/Regeneron, Daiichi Sankyo Europe GmbH

**Speakers' Bureau:** Roche/Genentech, Lilly, MSD Oncology, Merck Serono, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Pfizer, Novartis, Amgen, Mirati Therapeutics, Sanofi/Aventis

**Rina Hui**

**Honoraria:** Merck Sharp & Dohme, Novartis, Roche, AstraZeneca, Bristol Myers Squibb, Lilly, Pfizer, Seattle Genetics, Oncosec, Merck, Eisai

**Consulting or Advisory Role:** Merck Sharp & Dohme, AstraZeneca, Roche, Bristol Myers Squibb, Novartis, Lilly, Pfizer, Seattle Genetics, Oncosec, Merck, Eisai

**Research Funding:** AstraZeneca (Inst), Lilly (Inst), MSD (Inst), Roche (Inst), Seattle Genetics (Inst), OncoSec (Inst), Novartis (Inst), BMSi (Inst), Corvus Pharmaceuticals (Inst), Olema Pharmaceuticals (Inst), Janssen (Inst)

**Edward B. Garon**

**Consulting or Advisory Role:** Novartis, GlaxoSmithKline, Merck, Boehringer Ingelheim, Shionogi, Eisai, Bristol Myers Squibb, ABL Bio, Xilio Therapeutics, Natera, Sanofi/Regeneron, Lilly, Personalis, Gilead Sciences, AstraZeneca, AbbVie/ABBOTT, Ipsen

**Research Funding:** Merck (Inst), Genentech (Inst), AstraZeneca (Inst), Novartis (Inst), Lilly (Inst), Bristol Myers Squibb (Inst), Mirati Therapeutics (Inst), Dynavax Technologies (Inst), Iovance Biotherapeutics (Inst), Neon Therapeutics (Inst), EMD Serono (Inst), ABL Bio (Inst)

**Patents, Royalties, Other Intellectual Property:** Diagnostic and therapeutic use of "Motif Neopeptides" as defined by Cummings et al in Nature Cancer (Inst)

**Takayasu Kurata**

**Honoraria:** AstraZeneca, Ono Pharmaceutical, Bristol Myers Squibb, Chugai Pharma, Lilly, Boehringer Ingelheim, MSD Oncology, Pfizer, Nippon Kayaku

**Research Funding:** MSD Oncology (Inst), AstraZeneca (Inst), Lilly (Inst), Ono Pharmaceutical (Inst), Novartis (Inst), Takeda (Inst), Bristol Myers Squibb (Inst), Amgen

**Jhanelle E. Gray**

**Honoraria:** Merck Sharp & Dohme, Axiom Healthcare Strategies, Inivata, Jazz Pharmaceuticals, Merck, OncoCyte

**Consulting or Advisory Role:** AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, EMD Serono, Lilly, Sanofi, Merck Sharp & Dohme, Loxo, Jazz Pharmaceuticals, Novartis, AstraZeneca/MedImmune, Janssen Scientific Affairs, National Comprehensive Cancer Network

**Research Funding:** Merck (Inst), AstraZeneca (Inst), Bristol Myers Squibb (Inst), Boehringer Ingelheim (Inst), Genentech/Roche (Inst), G1 Therapeutics (Inst), Novartis (Inst), Pfizer (Inst), Ludwig Institute for Cancer Research (Inst), SWOG (Inst), Array BioPharma (Inst), ECOG-ACRIN (Inst)

**Travel, Accommodations, Expenses:** Merck Sharp & Dohme, Inivata, Merck, EMD Serono, Novartis, OncoCyte

**Paul Schwarzenberger**

**Employment:** Merck Sharp & Dohme LLC

**Stock and Other Ownership Interests:** Merck & Co, Inc

**Travel, Accommodations, Expenses:** AstraZeneca



**Erin Jensen**

**Employment:** Merck Sharp & Dohme LLC

**Stock and Other Ownership Interests:** Merck & Co, Inc

**M. Catherine Pietanza**

**Employment:** Merck Sharp & Dohme LLC

**Stock and Other Ownership Interests:** Merck & Co, Inc

**Delvys Rodríguez-Abreu**

**Consulting or Advisory Role:** Roche, Bristol Myers Squibb, MSD, AstraZeneca Spain, Novartis

**Speakers' Bureau:** Roche, Bristol Myers Squibb, MSD

**Travel, Accommodations, Expenses:** Roche, Bristol Myers Squibb, MSD

No other potential conflicts of interest were reported.

## APPENDIX

TABLE A1. Subsequent Anticancer Therapy

Subsequent Therapy	Pembrolizumab Plus Chemotherapy (n = 405 <sup>a</sup> )	Placebo Plus Chemotherapy (n = 202 <sup>a</sup> )
Any subsequent pharmacologic therapy	224 (55.3)	130 (64.4)
Any subsequent anti-PD-(L)1 therapy	103 (25.4) <sup>b</sup>	118 (58.4) <sup>b</sup>
First subsequent therapy	224 (55.3)	130 (64.4)
Pembrolizumab in-study crossover <sup>c</sup>	0	84 (41.2)
Pembrolizumab	24 (5.9)	7 (3.5)
Pembrolizumab + chemotherapy	2 (0.5)	0
Pembrolizumab + immunotherapy	1 (0.2)	0
Pembrolizumab + platinum doublet	3 (0.7)	0
Other anti-PD-(L)1 antibody	18 (4.4)	22 (10.9)
Other anti-PD-(L)1 antibody + chemotherapy	1 (0.2)	0
Other anti-PD-(L)1 antibody + immunotherapy	4 (1.0)	0
Other anti-PD-(L)1 antibody + targeted therapy	3 (0.7)	0
Other immunotherapy	2 (0.5)	0
Other immunotherapy + targeted therapy	2 (0.5)	1 (0.5)
Nonplatinum chemotherapy doublet	1 (0.2)	0
Nonplatinum chemotherapy + targeted therapy	26 (6.4)	2 (1.0)
Nonplatinum single-agent chemotherapy	70 (17.3)	7 (3.5)
Platinum doublet	24 (5.9)	2 (1.0)
Platinum doublet + targeted therapy	1 (0.2)	0
Platinum monotherapy	9 (2.2)	0
VEGF inhibitor	2 (0.5)	0
VEGF inhibitor + chemotherapy	14 (3.5)	1 (0.5)
VEGF inhibitor + platinum doublet	2 (0.5)	0
VEGF inhibitor + targeted therapy	1 (0.2)	0
Targeted therapy	14 (3.5)	4 (2.0)
Second subsequent therapy	115 (28.4)	52 (25.7)
Pembrolizumab	7 (1.7)	7 (3.5)
Pembrolizumab + chemotherapy	2 (0.5)	0
Pembrolizumab + platinum doublet	1 (0.2)	0
Other anti-PD-(L)1 antibody	15 (3.7)	2 (1.0)
Other anti-PD-(L)1 antibody + VEGF inhibitor	1 (0.2)	0
Other anti-PD-(L)1 antibody + targeted therapy	1 (0.2)	0
Nonplatinum chemotherapy doublet	1 (0.2)	0
Nonplatinum chemotherapy + targeted therapy	2 (0.5)	8 (4.0)
Nonplatinum single-agent chemotherapy	47 (11.6)	21 (10.4)
Platinum doublet	8 (2.0)	6 (3.0)
Platinum doublet + targeted therapy	1 (0.2)	0
Platinum monotherapy	0	1 (0.5)
VEGF inhibitor + chemotherapy	4 (1.0)	1 (0.5)
Targeted therapy	25 (6.2)	6 (3.0)

(continued on following page)

**TABLE A1.** Subsequent Anticancer Therapy (continued)

<b>Subsequent Therapy</b>	<b>Pembrolizumab Plus Chemotherapy (n = 405<sup>a</sup>)</b>	<b>Placebo Plus Chemotherapy (n = 202<sup>a</sup>)</b>
Third subsequent therapy	48 (11.9)	19 (9.4)
Pembrolizumab	3 (0.7)	0
Pembrolizumab + chemotherapy	1 (0.2)	0
Other anti-PD-(L)1 antibody	9 (2.2)	3 (1.5)
Other anti-PD-(L)1 antibody + VEGF inhibitor + platinum doublet	1 (0.2)	0
Nonplatinum chemotherapy + targeted therapy	1 (0.2)	0
Platinum doublet	6 (1.5)	2 (1.0)
Platinum monotherapy	1 (0.2)	0
Single-agent chemotherapy	15 (3.7)	8 (4.0)
VEGF inhibitor	1 (0.2)	0
VEGF inhibitor + chemotherapy	1 (0.2)	1 (0.5)
Targeted therapy	9 (2.2)	5 (2.5)
Fourth subsequent therapy	21 (5.2)	10 (5.0)
Pembrolizumab	0	0
Pembrolizumab + platinum doublet	1 (0.2)	1 (0.5)
Other anti-PD-(L)1 antibody	3 (0.7)	1 (0.5)
Nonplatinum chemotherapy doublet	0	1 (0.5)
Nonplatinum chemotherapy + targeted therapy	2 (0.5)	0
Nonplatinum single-agent chemotherapy	9 (2.2)	4 (2.0)
VEGF inhibitor + chemotherapy	1 (0.2)	0
Targeted therapy	5 (1.2)	3 (1.5)
Fifth subsequent therapy	8 (2.0)	3 (1.5)
Pembrolizumab	0	0
Other anti-PD-(L)1 antibody	1 (0.2)	0
Nonplatinum single-agent chemotherapy	3 (0.7)	3 (1.5)
Platinum doublet	1 (0.2)	0
Platinum monotherapy	1 (0.2)	0
VEGF inhibitor + chemotherapy	1 (0.2)	0
Targeted therapy	1 (0.2)	0
Sixth subsequent therapy	6 (1.5)	0
Pembrolizumab	0	0
Other anti-PD-(L)1 antibody	2 (0.5)	0
Other anti-PD-(L)1 antibody + VEGF inhibitor + platinum doublet	1 (0.2)	0
Nonplatinum chemotherapy doublet	1 (0.2)	0
VEGF inhibitor	1 (0.2)	0
Targeted therapy	1 (0.2)	0
Seventh subsequent therapy	3 (0.7)	0
Platinum doublet	2 (0.5)	0
Nonplatinum single-agent chemotherapy	1 (0.2)	0

NOTE. Data presented as No. (%).

Abbreviations: BICR, blinded independent central review; PD-L1, programmed cell death ligand 1; VEGF, vascular endothelial growth factor.

<sup>a</sup>Percentages were calculated on the basis of the as-treated population.

<sup>b</sup>Including patients who received on-study second-course pembrolizumab.

<sup>c</sup>Eligible patients in the placebo plus chemotherapy group with confirmed progressive disease per BICR were allowed to cross over to pembrolizumab monotherapy for up to 35 cycles.

**TABLE A2.** Tumor Response

Response	ITT Population (N = 616)		PD-L1 TPS ≥ 50% (n = 202 <sup>a</sup> )		PD-L1 TPS 1%-49% (n = 186 <sup>a</sup> )		PD-L1 TPS < 1% (n = 190 <sup>a</sup> )	
	Pembrolizumab Plus Chemotherapy (n = 410)	Placebo Plus Chemotherapy (n = 206)	Pembrolizumab Plus Chemotherapy (n = 132)	Placebo Plus Chemotherapy (n = 70)	Pembrolizumab Plus Chemotherapy (n = 128)	Placebo Plus Chemotherapy (n = 58)	Pembrolizumab Plus Chemotherapy (n = 127)	Placebo Plus Chemotherapy (n = 63)
ORR, <sup>b</sup> % (95% CI)	48.3 (43.4 to 53.2)	19.9 (14.7 to 26.0)	62.1 (53.3 to 70.4)	25.7 (16.0 to 37.6)	50.0 (41.0 to 59.0)	20.7 (11.2 to 33.4)	33.1 (25.0 to 42.0)	14.3 (6.7 to 25.4)
Best overall response, No. (%)								
CR	10 (2.4)	1 (0.5)	4 (3.0)	0	4 (3.1)	1 (1.7)	1 (0.8)	0
PR	188 (45.9)	40 (19.4)	78 (59.1)	18 (25.7)	60 (46.9)	11 (19.0)	41 (32.3)	9 (14.3)
SD <sup>c</sup>	149 (36.3)	104 (50.5)	33 (25.0)	28 (40.0)	46 (35.9)	33 (56.9)	58 (45.7)	36 (57.1)
PD	37 (9.0)	36 (17.5)	6 (4.5)	16 (22.9)	15 (11.7)	7 (12.1)	15 (11.8)	9 (14.3)
Not evaluable <sup>d</sup>	12 (2.9)	8 (3.9)	5 (3.8)	1 (1.4)	0	2 (3.4)	7 (5.5)	4 (6.3)
No assessment <sup>e</sup>	14 (3.4)	17 (8.3)	6 (4.5)	7 (10.0)	3 (2.3)	4 (6.9)	5 (3.9)	5 (7.9)
DOR, months, <sup>f</sup> median (range)	12.7 (1.1+ to 68.3+)	7.1 (2.4 to 31.5)	15.3 (1.2+ to 68.3+)	7.1 (3.4 to 31.5)	13.6 (2.1+ to 67.6+)	7.6 (2.4 to 31.0+)	10.8 (1.1+ to 59.4+)	7.8 (4.1 to 28.3+)
DOR ≥ 4 years, <sup>f</sup> No. (%)	27 (20.2)	NA <sup>g</sup>	16 (28.2)	NA <sup>g</sup>	6 (14.1)	NA <sup>g</sup>	3 (9.6) <sup>g</sup>	NA <sup>g</sup>
Time to response, months, median (range)	2.4 (1.1-19.3)	1.4 (1.2-13.6)	1.6 (1.1-19.1)	1.5 (1.2-13.6)	2.6 (1.1-19.3)	2.0 (1.2-11.1)	2.7 (1.2-19.2)	1.4 (1.2-4.8)

NOTE. +, no PD by the time of last disease assessment.

Abbreviations: CR, complete response; DOR, duration of response; ITT, intention-to-treat; ORR, objective response rate; PD, progressive disease; PD-L1, programmed cell death ligand 1; PR, partial response; SD, stable disease; TPS, tumor proportion score.

<sup>a</sup>Excludes 38 patients for whom PD-L1 expression could not be evaluated.

<sup>b</sup>Per Response Evaluation Criteria in Solid Tumors version 1.1 by blinded independent central review.

<sup>c</sup>Stable disease includes both stable disease and non-CR/non-PD.

<sup>d</sup>Postbaseline assessment(s) available but not evaluable or CR/PR/SD < 6 weeks from random assignment.

<sup>e</sup>No postbaseline assessment available for response evaluation.

<sup>f</sup>On the basis of Kaplan-Meier estimate.

<sup>g</sup>Fewer than four patients at risk after 24 months.

**TABLE A3.** Summary of AEs in Patients Who Received  $\geq 1$  Dose of Study Treatment

Event	Pembrolizumab Plus Chemotherapy (n = 405)		Placebo Plus Chemotherapy (n = 202)	
	Any grade	Grade 3-5	Any grade	Grade 3-5
Any AE (all-cause)	404 (99.8)		200 (99.0)	
Grade 3-5	295 (72.8)		136 (67.3)	
Led to death <sup>a</sup>	29 (7.2)		14 (6.9)	
Led to discontinuation of any treatment component	145 (35.8)		35 (17.3)	
Treatment-related	377 (93.1)		183 (90.6)	
Grade 3-5	212 (52.3)		85 (42.1)	
Led to discontinuation of any treatment component <sup>b</sup>	111 (27.4)		20 (9.9)	
Led to discontinuation of pembrolizumab or placebo	71 (17.5)		11 (5.4)	
Led to discontinuation of pemetrexed	96 (23.7)		17 (8.4)	
AEs occurring in $\geq 15\%$ of patients in either treatment group	Any grade	Grade 3-5	Any grade	Grade 3-5
Nausea	235 (58.0)	14 (3.5)	108 (53.5)	8 (4.0)
Anemia	196 (48.4)	77 (19.0)	98 (48.5)	36 (17.8)
Fatigue	174 (43.0)	31 (7.7)	80 (39.6)	7 (3.5)
Constipation	144 (35.6)	4 (1.0)	67 (33.2)	1 (0.5)
Diarrhea	131 (32.3)	21 (5.2)	44 (21.8)	6 (3.0)
Decreased appetite	122 (30.1)	5 (1.2)	64 (31.7)	2 (1.0)
Neutropenia	114 (28.1)	68 (16.8)	50 (24.8)	24 (11.9)
Vomiting	109 (26.9)	16 (4.0)	48 (23.8)	6 (3.0)
Cough	104 (25.7)	0	62 (30.7)	0
Dyspnea	103 (25.4)	17 (4.2)	54 (26.7)	8 (4.0)
Peripheral edema	103 (25.4)	2 (0.5)	35 (17.3)	0
Asthenia	90 (22.2)	27 (6.7)	47 (23.3)	7 (3.5)
Pyrexia	89 (22.0)	1 (0.2)	34 (16.8)	1 (0.5)
Rash	89 (22.0)	8 (2.0)	27 (13.4)	3 (1.5)
Thrombocytopenia	77 (19.0)	35 (8.6)	30 (14.9)	15 (7.4)
Lacrimation increased	75 (18.5)	0	22 (10.9)	0
Arthralgia	71 (17.5)	5 (1.2)	28 (13.9)	1 (0.5)
Back pain	71 (17.5)	7 (1.7)	27 (13.4)	4 (2.0)
Dizziness	62 (15.3)	3 (0.7)	23 (11.4)	0
Immune-mediated AEs and infusion reactions	113 (27.9)	52 (12.8)	27 (13.4)	9 (4.5)
Hypothyroidism	32 (7.9)	2 (0.5)	5 (2.5)	0
Hyperthyroidism	20 (4.9)	0	7 (3.5)	0
Pneumonitis	20 (4.9)	12 (3.0)	6 (3.0)	4 (2.0)
Colitis	13 (3.2)	7 (1.7)	0	0
Infusion reactions	12 (3.0)	2 (0.5)	3 (1.5)	0
Severe skin reactions	10 (2.5)	10 (2.5)	5 (2.5)	4 (2.0)
Nephritis	8 (2.0)	6 (1.5)	0	0
Hepatitis	7 (1.7)	6 (1.5)	0	0
Hypophysitis	3 (0.7)	0	0	0

(continued on following page)

**TABLE A3.** Summary of AEs in Patients Who Received ≥ 1 Dose of Study Treatment (continued)


Event	Pembrolizumab Plus Chemotherapy (n = 405)		Placebo Plus Chemotherapy (n = 202)	
Myositis	3 (0.7)	0	0	0
Pancreatitis	4 (1.0)	3 (0.7)	0	0
Adrenal insufficiency	2 (0.5)	1 (0.2)	1 (0.5)	1 (0.5)
Encephalitis	2 (0.5)	2 (0.5)	0	0
Type 1 diabetes mellitus	2 (0.5)	2 (0.5)	0	0
Vasculitis	2 (0.5)	1 (0.2)	0	0
Cholangitis sclerosing	1 (0.2)	1 (0.2)	0	0
Myocarditis	1 (0.2)	1 (0.2)	0 </td <td>0</td>	0
Thyroiditis	1 (0.2)	0	0	0
Guillain-Barré syndrome	1 (0.2)	1 (0.2)	0	0

NOTE. Data presented as No. (%).

Abbreviation: AE, adverse event.

<sup>a</sup>Eight patients (2.0%) in the pembrolizumab plus chemotherapy group and two patients (1.0%) in the placebo plus chemotherapy group died from AEs attributed to study treatment by the investigator, all reported previously.<sup>2</sup>

<sup>b</sup>Forty-one patients (10.1%) in the pembrolizumab plus chemotherapy group and three (1.5%) in the placebo plus chemotherapy group discontinued any treatment component because of an immune-mediated AE or infusion reaction.



**FIG A1.** Kaplan-Meier estimates of (A) OS and (B) PFS per Response Evaluation Criteria in Solid Tumors version 1.1 by blinded independent central review in patients with PD-L1 TPS ≥ 1%. Chemo, chemotherapy; OS, overall survival; PD-L1, programmed cell death ligand 1; pembro, pembrolizumab; PFS, progression-free survival; TPS, tumor proportion score.